Form 4: Nektar Director Brainard Granted 8,000 Stock Options

Nektar Therapeutics director Diana Brainard was granted 8,000 stock options with an exercise price of $56.90, vesting monthly over one year starting September 30, 2025.

Summary

• Diana Brainard, a Director of Nektar Therapeutics (NKTR), was granted 8,000 stock options.
• The options have an exercise price of $56.90 per share.
• The grant date for these options is September 30, 2025.
• The options will vest in substantially equal monthly installments over a one-year period, commencing on September 30, 2025.
• The expiration date for these stock options is September 29, 2033.
• Following this transaction, Diana Brainard beneficially owns 8,000 derivative securities.

Sentiment

Score: 6

Explanation: The grant of stock options to a director is a standard compensation practice, generally viewed as a neutral to slightly positive event as it aligns the director's interests with long-term shareholder value.

Positives

• The grant of stock options to Director Diana Brainard aligns her interests with long-term shareholder value creation.
• The vesting schedule over one year encourages continued engagement and performance from the director.

Future Outlook

The granted stock options will vest in substantially equal monthly installments over a one-year period beginning on September 30, 2025, aligning the director's future compensation with company performance.

Industry Context

This transaction represents a routine compensation event for a director in the biotechnology industry, utilizing stock options to incentivize long-term performance and align management interests with shareholders.

Related Party Transactions

• The grant of stock options to Diana Brainard, a director of Nektar Therapeutics, constitutes a related party transaction as it involves compensation between the company and a member of its board.

Stakeholder Impact

• Shareholders: The grant aims to align the director's interests with shareholder value creation, potentially leading to improved long-term performance. However, future exercise of options could lead to minor dilution.
• Management: The director's compensation structure is enhanced, providing an incentive for strategic oversight.

Next Steps

• The 8,000 stock options will vest in substantially equal monthly installments over the one-year period beginning September 30, 2025.
• The director may exercise the vested options at the exercise price of $56.90 per share before the expiration date of September 29, 2033.

Key Dates

Keywords

Nektar Therapeutics, NKTR, Diana Brainard, Stock Option, Director Compensation, SEC Form 4, Beneficial Ownership, Derivative Securities